Clinical trials: sponsored by Bristol-Myers Squibb
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma, Hepatoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT04567615
- Testing
- Nivolumab, Relatlimab
- Where
- 65 sites in Argentina, Brazil and 15 more
- Volunteers
- 266 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating…
- Trial name
- CheckMate 816 (NCT02998528)
- Testing
- Nivolumab, Cisplatin, Vinorelbine
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus…
- Trial name
- CheckMate040 (NCT01658878)
- Testing
- Nivolumab, Sorafenib, Ipilimumab
- Where
- 60 sites in United States, Canada and 11 more
- Volunteers
- 657 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- CheckMate 650 (NCT02985957)
- Testing
- Nivolumab, Ipilimumab, Cabazitaxel
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 351 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely…
- Trial name
- UNITE-001 (NCT05919823)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 28 sites in China
- Volunteers
- 202 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Non-Small Cell Lung Cancer
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
- Trial name
- CheckMate 9LA (NCT03215706)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 116 sites in United States, Argentina and 17 more
- Volunteers
- 719 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
The purpose of this study is to evaluate Deucravacitinib concentrations in the breast milk and plasma of healthy lactating female participants.
- Trial name
- NCT06476834
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
- Trial name
- NCT05730725
- Testing
- BMS-986322
- Where
- 35 sites in United States, Australia and 3 more
- Volunteers
- 109 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
- Trial name
- CheckMate 577 (NCT02743494)
- Testing
- Nivolumab
- Where
- 204 sites in United States, Argentina and 29 more
- Volunteers
- 794 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
- Trial name
- NCT03369223
- Testing
- BMS-986249, Nivolumab, Ipilimumab
- Where
- 45 sites in United States, Argentina and 9 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms by Site
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for…
- Trial name
- NCT03656718
- Testing
- nivolumab, rHuPH20
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 139 people
- Sponsor
- Bristol-Myers Squibb
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients…
- Trial name
- CheckMate 227 (NCT02477826)
- Testing
- Nivolumab, Ipilimumab, Carboplatin
- Where
- 290 sites in United States, Argentina and 31 more
- Volunteers
- 2,747 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
- Trial name
- NCT05478499
- Testing
- Deucravacitinib
- Where
- 29 sites in United States, France and 3 more
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT01592370
- Testing
- Nivolumab, Ipilimumab, Lirilumab
- Where
- 43 sites in United States, Belgium and 4 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Pancreatic Cancer
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus…
- Trial name
- NCT03184870
- Testing
- BMS-813160, Nivolumab, Nab-paclitaxel
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 332 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid…
- Trial name
- NCT05168202
- Testing
- CC-95251, Azacitidine, Venetoclax
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb